Single Ascending Dose Study for Evaluation of Safety, Tolerability and Pharmacokinetics of L606

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1

Total Enrollment

52 participants

Study Classification

INTERVENTIONAL

Study Start Date

2018-11-09

Study Completion Date

2020-05-12

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The primary objective of this study is to evaluate the Pharmacokinetics, Safety and Tolerability of L606 (Liposomal Treprostinil) Inhalation Solution in Single Ascending Dose study design in healthy volunteers.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

A Phase 3 Study to Evaluate the Safety and Tolerability of L606 in Subjects With PAH or PH-ILD

NCT04691154

Pulmonary Arterial Hypertension Pulmonary Hypertension Due to Lung Diseases

ACTIVE_NOT_RECRUITING PHASE3

A Phase 3 Study to Evaluate the Safety and Efficacy L606 in Participants With PH-ILD

NCT07285655

Pulmonary Hypertension Due to Lung Disease (Disorder)

NOT_YET_RECRUITING PHASE3

Investigation of the Safety and Pharmacology of Dry Powder Inhalation of Treprostinil

NCT03399604

Primary Pulmonary Hypertension

COMPLETED PHASE3

Pharmacokinetics, Safety and Tolerability of Treprostinil Inhalation Powder in Healthy Normal Volunteers

NCT03464864

Pulmonary Arterial Hypertension

COMPLETED PHASE1

A Study to Learn About the Treatment LTP001 in Healthy Participants (Part A) and in Participants With PAH (Part B)

NCT06649110

Healthy Volunteers, Pulmonary Arterial Hypertension

RECRUITING PHASE1/PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

L606 (Liposomal Treprostinil) Inhalation Solution and dedicated inhalation system is developed by Pharmosa Biopharm Inc. intended to improve the inconvenience, as one of the greatest impediments to patient satisfaction to current inhaled treprostinil therapy. Pharmosa's liposomal technology offers sustained release of treprostinil which enable bid treatment instead of conventional qid treatment offered by current inhaled treprostinil therapy for treatment of patients with PAH (WHO Group 1).

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Pulmonary Arterial Hypertension

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

SEQUENTIAL

Primary Study Purpose

OTHER

Blinding Strategy

DOUBLE

Participants Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

placebo

placebo group

Group Type PLACEBO_COMPARATOR

L606 Inhalation System

Intervention Type DEVICE

Single ascending dose

Placebo Solution

Intervention Type OTHER

Single ascending dose

L606 Liposomal inhalation solution

Liposomal inhalation solution

Group Type EXPERIMENTAL

L606 (Liposomal Treprostinil) Inhalation Solution 51ug

Intervention Type DRUG

Single ascending dose

L606 Inhalation System

Intervention Type DEVICE

Single ascending dose

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

L606 (Liposomal Treprostinil) Inhalation Solution 51ug

Single ascending dose

Intervention Type DRUG

L606 Inhalation System

Single ascending dose

Intervention Type DEVICE

Placebo Solution

Single ascending dose

Intervention Type OTHER

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Drug: L606 (Liposomal Treprostinil) Inhalation Solution Device: L606 Inhalation Solution

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Males or females, of any race, 18 to 50 years of age, inclusive, at Screening.
2. Body mass index between 18.5 and 32.0 kg/m2, inclusive, at Screening.
3. In good health, determined by no clinically significant findings from medical history, physical examination, 12 lead ECG, vital sign measurements, and clinical laboratory evaluations (congenital nonhemolytic hyperbilirubinemia \[eg, Gilbert's syndrome\] is not acceptable) at Screening or Check in as assessed by the Investigator (or designee).
4. Ability of the subject to generate spirometry according to minimum ATS/ERS guidance criteria.
5. Females will not be pregnant or lactating, and females of childbearing potential and males will agree to use contraception as detailed in Section 6.6.
6. Able to comprehend and willing to sign an ICF and to abide by the study restrictions.
7. Agree to abstain from consuming alcohol from 72 hours prior to Check-in.
8. Agree to refrain from strenuous exercise from 7 days prior to Check-in.
9. Agree to abstain from consuming foods and beverages containing poppy seeds, grapefruit, or Seville oranges from 7 days prior to Check-in.
10. Agree to abstain from consuming caffeine-containing foods and beverages from 48 hours prior to Check-in.
11. Agree to abstain from consuming carbonated drinks (including sparkling water and soda) from 48 hours prior to Check-in and until end of study.

Exclusion Criteria

1. Clinically relevant abnormalities identified during Screening, physical examination, 12 lead ECG, or laboratory examinations.
2. Clinically significant history of hepatic, renal, hematological, pulmonary, cardiovascular, gastrointestinal, neurological, respiratory, endocrine, genitourinary, and/or musculoskeletal disease, glaucoma, psychiatric disorder, or any other chronic disease, whether controlled by medication or not.
3. History of anaphylaxis, significant hypersensitivity, intolerance, or allergy to any drug compound, food, or other substance, unless deemed not clinically significant by the Investigator (or designee).
4. History of postural hypotension, unexplained syncope, or hypertension.
5. History of asthma, chronic obstructive pulmonary disease (COPD), or reactive airways conditions or findings consistent with asthma or COPD on spirometry testing.
6. Blood pressure \<90 mmHg systolic or \<50 mmHg diastolic after supine for 5 minutes at Screening or Check in upon repeat testing.
7. Blood pressure \>150 mmHg systolic or \>90 mmHg diastolic after supine for 5 minutes at Screening or Check in upon repeat testing.
8. Pulse rate \>100 bpm after supine for 5 minutes at Screening or Check-in upon repeat testing.
9. Have a pre-existing condition that could interfere with the absorption, distribution, metabolism, or excretion of drugs. Cholecystectomy is permitted if done at least 10 days before enrollment.
10. Use tobacco- or nicotine-containing products within 6 months prior to Check-in, or have a history of \>1 pack cigarettes daily use over multiple years of smoking.
11. History of alcoholism or drug/chemical abuse within 2 years prior to Check-in.
12. Have a history of alcohol abuse or a history of or current impairment of organ function reasonably related to alcohol abuse.
13. Have a history of or current evidence of abuse of licit or illicit drugs or a positive urine screen for drugs of abuse.
14. Alcohol consumption of \>21 units per week. One unit of alcohol equals 12 oz (360 mL) beer, 1.5 oz (45 mL) liquor, or 5 oz (150 mL) wine.
15. Positive urine drug screen (including alcohol and cotinine) at Screening and/or Check-in.
16. Positive hepatitis panel and/or positive human immunodeficiency virus test at Screening.
17. Participation in a clinical study involving administration of an investigational drug (new chemical entity) within 30 days prior to Check-in.
18. Use or intend to use any medications/products known to alter drug absorption, metabolism, or elimination processes, including St. John's Wort, within 30 days prior to Check-in, unless deemed acceptable by the Investigator (or designee).
19. Use or intend to use any prescription medications/products within 14 days prior to Check-in with the exception of hormone replacement therapy, oral, implantable, transdermal, injectable, or intrauterine contraceptives, unless deemed acceptable by the Investigator (or designee).
20. Use or intend to use slow-release medications/products considered to still be active within 14 days prior to Check-in, unless deemed acceptable by the Investigator (or designee).
21. Use or intend to use any nonprescription medications/products or herbal supplements within 7 days prior to Check-in, unless deemed acceptable by the Investigator (or designee). Use of nonsteroidal anti inflammatory drugs or aspirin is prohibited within 14 days prior to Check-in.
22. Receipt of blood products within 2 months prior to Check-in.
23. Donation of blood, plasma, and platelets, or the loss of a significant volume of blood (\>450 mL) within 6 weeks prior to Screening.
24. Poor peripheral venous access.
25. Have a history of bleeding problems or abnormal bleeding tendencies.
26. Platelet or coagulation factor levels below the lower limit of normal, unless considered not clinically significant by the Investigator.
27. Have previously completed or withdrawn from this study or any other study investigating treprostinil, and have previously received the investigational product.
28. History of any recent infection within 2 weeks of Check-in.
29. In the opinion of the Investigator (or designee), should not participate in this study.

Minimum Eligible Age

18 Years

Maximum Eligible Age

50 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes